Priya, a 28-year-old graphic designer in Minneapolis, started aripiprazole for bipolar II depression on a Friday and by Monday morning she could not sit through a meeting, could not lie still in bed, could not stop pacing the apartment her husband had begun watching her circle like a zoo animal. She described the feeling as having electricity running through her muscles, an unbearable need to move that no amount of movement satisfied. By Wednesday she was crying constantly and told her husband she would rather be dead than feel this way for one more hour. He drove her to the psychiatric emergency department of a downtown hospital where a sharp resident immediately recognized severe akathisia, gave her propranolol and lorazepam, called the prescribing psychiatrist, and arranged same-day follow-up. The aripiprazole was discontinued, the symptoms resolved within seventy-two hours, and Priya later said the most frightening part of the experience was how quickly a routine medication start had turned into active suicidality without anyone, including her, recognizing what was happening until she was already at the edge.
Priya’s case captures why akathisia treatment is among the most urgent clinical tasks in psychiatry, and why missing or misattributing the diagnosis carries genuine mortality risk. Akathisia is a syndrome of inner restlessness combined with observable repetitive movement, induced most often by antipsychotic medications but also by selective serotonin reuptake inhibitors, antiemetics, and certain other dopamine-modulating drugs. The word comes from Greek, meaning inability to sit, and that captures the central phenomenology. What patients describe is not anxiety, although it overlaps with anxiety, and not agitation in the ordinary sense, although it can produce agitated behavior. The peer-reviewed literature has documented links between severe akathisia and suicide attempts going back to the 1980s, and several drug labels carry specific warnings tied to this association.
Recognising akathisia: subjective restlessness plus objective movement
Akathisia has two essential components. The subjective component is an internal sense of restlessness that patients describe as a need to move, an inability to be still, electricity in the muscles, crawling sensations, or simply unbearable distress. The objective component is repetitive movement: foot tapping, leg crossing and uncrossing, rocking from foot to foot when standing, pacing, or shifting in the chair. Either component without the other does not constitute akathisia in the traditional sense, although milder presentations with predominantly subjective symptoms have been described. Onset is typically within hours to weeks of starting or increasing a causative medication, though tardive akathisia emerging months or years into therapy is also recognized. Severity ranges from a mild, manageable restlessness to the catastrophic distress Priya experienced, where patients become convinced they cannot survive another hour in their own bodies.
The suicide risk literature: why akathisia is a psychiatric emergency
Multiple case series and pharmacovigilance reports have linked severe akathisia to suicidal ideation, suicide attempts, and completed suicide. The mechanism appears to involve the unbearable nature of the dysphoria itself rather than a depressive cognitive shift, and patients often describe wanting to die specifically to escape the physical sensation. The U.S. Food and Drug Administration’s adverse event reporting system has accumulated thousands of reports linking various psychotropic medications to akathisia followed by suicidal behavior, and several SSRI labels include language about activation syndromes that overlap with akathisia. Clinicians who fail to ask about restlessness when patients return reporting worsening mood after a medication change risk missing the actual cause and treating a phantom depression while the underlying drug-induced syndrome continues. Neuroleptic malignant syndrome represents a different antipsychotic emergency with overlapping motor features.
The BARS scale: standardized akathisia assessment
The Barnes Akathisia Rating Scale, abbreviated BARS, is the most widely used clinical instrument for measuring akathisia severity. Developed by Thomas Barnes in 1989, the scale rates objective movements observed during sitting and standing, subjective awareness of restlessness, subjective distress related to the restlessness, and a global clinical assessment combining all elements. The global score ranges from absent to severe, and any score of moderate or higher generally warrants intervention. Brief and standardized, the BARS can be completed in five minutes during any medication management visit, yet it is rarely performed in routine community psychiatric practice. If your prescriber has placed you on an antipsychotic and never asked you specifically about inner restlessness or watched you sit and stand, you have probably never received a formal akathisia screen.
Treatment hierarchy: reduce, switch, or add
Effective akathisia treatment follows a hierarchical approach that begins with the offending medication itself. Where clinically feasible, dose reduction is the simplest intervention and may resolve symptoms within days. When dose reduction is not possible because of underlying illness severity, switching to a different antipsychotic with a lower akathisia profile is the next step. Quetiapine, olanzapine, and clozapine generally produce less akathisia than aripiprazole, lurasidone, or first-generation agents, although individual responses vary. When switching is impractical or undesirable, adjunctive medications can suppress symptoms while the primary agent is continued. The classic first-line adjunct is propranolol, a beta-blocker that crosses the blood-brain barrier and reduces akathisia at doses of 30 to 80 milligrams per day in divided doses.
- Propranolol 10 to 30 mg three times daily, titrate as blood pressure permits
- Mirtazapine 7.5 to 15 mg at bedtime, particularly for SSRI-induced or treatment-resistant cases
- Benzodiazepines (lorazepam, clonazepam) for short-term distress relief and bridge therapy
- Anticholinergics (benztropine, trihexyphenidyl) when parkinsonian features coexist with akathisia
- Cyproheptadine 8 to 16 mg per day as a serotonergic alternative
- VMAT2 inhibitors and gabapentin have emerging evidence in refractory cases
Distinguishing akathisia from anxiety and agitation
The single most consequential clinical error in akathisia management is mistaking the syndrome for worsening anxiety, agitation related to underlying psychotic illness, or a depressive exacerbation. The differentiator most patients can articulate when asked is the predominantly motor and physical quality of akathisia, distinct from the cognitive and affective dimensions of primary anxiety. Anxiety produces racing thoughts, worry, and somatic symptoms like palpitations and shortness of breath. Akathisia produces the specific sensation of needing to move, often without accompanying worry content. A practical bedside test is to ask whether the symptoms started after a recent medication change, whether they are temporally relieved by walking or pacing, and whether they feel located in the body rather than the mind. Affirmative answers should prompt a presumptive akathisia diagnosis. Acute reactive psychosis can produce agitation that is sometimes confused with severe akathisia in the emergency setting.
Patient experience reports and the language of akathisia
Patient narratives consistently describe akathisia as one of the most distressing experiences in human suffering, often using language stronger than that applied to severe physical pain. Online communities of people who have lived through it use phrases like restless legs of the soul, an electric current that will not stop, and being trapped in your own body. Reading these accounts can be clinically useful for prescribers who have never experienced the syndrome themselves and may underestimate its severity. The U.S. Food and Drug Administration’s adverse event database at fda.gov contains thousands of patient and caregiver reports detailing akathisia experiences. Validating the patient’s description rather than reframing it as anxiety builds the therapeutic alliance needed to navigate medication decisions during a frightening period.
Anticholinergics, parkinsonism, and the tricky overlap
Antipsychotics can produce akathisia, parkinsonism, acute dystonia, and tardive dyskinesia, sometimes simultaneously. Distinguishing pure akathisia from akathisia coexisting with drug-induced parkinsonism matters because the treatments differ. Anticholinergic medications such as benztropine and trihexyphenidyl are highly effective for parkinsonism (rigidity, bradykinesia, tremor, masked facies) but provide modest or no benefit for pure akathisia and can worsen tardive dyskinesia. When a patient has a stiff, slow gait alongside restlessness, an anticholinergic added to the regimen often helps both components by relieving the parkinsonian contribution to overall distress. When the gait is normal and restlessness is the chief complaint, propranolol or mirtazapine is the better choice. Careful examination separates these phenotypes.
Finding psychiatrists who recognize akathisia
Identifying clinicians comfortable diagnosing and treating akathisia is similar to finding TD-knowledgeable specialists. Academic medical centers, neuropsychiatry programs, and movement disorder clinics are reliable starting points. When establishing care with a new psychiatrist, ask whether they screen for akathisia routinely, what scale they use, what their first-line treatment is, and whether they have prescribed propranolol or mirtazapine for the indication. Telehealth psychiatrists experienced in medication management can often recognize akathisia via video, particularly if a family member can describe observed restlessness. Tapering off antidepressants sometimes uncovers underlying activation syndromes that resemble akathisia and require careful differentiation. Patient advocacy groups including MISSD (Medication-Induced Suicide Prevention and Education Foundation) maintain clinician directories and patient resources.
Frequently asked questions about akathisia
How quickly does akathisia start after a medication change?
Acute akathisia typically emerges within hours to days of starting or increasing a causative agent. Some cases develop over weeks. Tardive akathisia can appear months or years into therapy or even after discontinuation.
Can SSRIs and SNRIs cause akathisia?
Yes, particularly fluoxetine, paroxetine, sertraline, and venlafaxine. SSRI-induced akathisia is part of what some clinicians call activation syndrome and is a recognized cause of treatment-emergent suicidal ideation, especially in adolescents and young adults.
What if propranolol does not help my akathisia?
Mirtazapine, benzodiazepines, cyproheptadine, gabapentin, and switching the offending antipsychotic are next-line options. Some refractory cases respond to clozapine substitution or VMAT2 inhibitors. Persistent symptoms warrant subspecialty referral.
Is akathisia permanent?
Acute akathisia usually resolves within days to weeks of stopping the causative agent. Tardive akathisia can persist long-term and may require ongoing treatment. Early recognition and intervention produce better outcomes.
Should I stop my medication myself if I think I have akathisia?
Contact your prescriber urgently rather than stopping abruptly, as sudden discontinuation of some psychotropics carries its own risks. If you cannot reach your prescriber and feel unsafe, go to a psychiatric emergency department for assessment.
The bottom line
Severe akathisia is a treatable but potentially lethal medication-induced syndrome that every prescriber and every patient on psychotropics should be able to recognize. The combination of unbearable inner restlessness, observable repetitive movement, and acute onset after medication change marks the diagnosis, and the suicide risk literature establishes the urgency. Propranolol, mirtazapine, dose reduction, antipsychotic switching, and benzodiazepine bridge therapy form the toolkit, with subspecialty consultation reserved for refractory cases. The National Institute of Mental Health at nih.gov publishes patient-facing information on medication side effects that patients and families can use to recognize akathisia early.
If you are in crisis or experiencing thoughts of suicide, call or text 988 to reach the Suicide and Crisis Lifeline, available twenty-four hours a day across the United States.
This article is for educational purposes only and does not constitute medical advice. Always consult a qualified psychiatrist or other licensed prescriber before making any changes to your medication regimen, particularly when symptoms suggest akathisia or another acute drug-induced syndrome.